In this article, we comment on the article published by Yu . By employing LASSO regression and Cox proportional hazard models, the article identified nine significant variables affecting survival, including body mass index, Karnofsky performance status, and tumor-node-metastasis staging. We firmly concur with Yu regarding the vital significance of clinical prediction models (CPMs), including logistic regression and Cox regression for assessment in esophageal carcinoma (EC). However, the nomogram's limitations and the complexities of integrating genetic factors pose challenges. The integration of immunological data with advanced statistics offers new research directions. High-throughput sequencing and big data, facilitated by machine learning, have revolutionized cancer research but require substantial computational resources. The future of CPMs in EC depends on leveraging these technologies to improve predictive accuracy and clinical application, addressing the need for larger datasets, patient-reported outcomes, and regular updates for clinical relevance.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755996 | PMC |
http://dx.doi.org/10.4251/wjgo.v17.i2.101379 | DOI Listing |
PLoS One
March 2025
Centre for Proteomic Research, Biological Sciences and Institute for Life Sciences, Building 85, University of Southampton, Southampton, United Kingdom.
Oesophageal adenocarcinoma (OAC) is the 7th most common cancer in the United Kingdom (UK) and remains a significant health challenge. This study presents a proteomic analysis of seven OAC donors complementing our previous neoantigen identification study of their human leukocyte antigen (HLA) immunopeptidomes. Our small UK cohort were selected from donors undergoing treatment for OAC.
View Article and Find Full Text PDFClin Transl Oncol
March 2025
Pathology Department, Hospital del Mar, Pompeu Fabra University, Hospital del Mar Research Institute, Barcelona, Spain.
Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA.
View Article and Find Full Text PDFCancer Sci
March 2025
Translational Medicine Research Center, Department of Pathology & Shanxi Key Laboratory of Carcinogenesis and Translational Research of Esophageal Cancer, Shanxi Medical University, Taiyuan, Shanxi, China.
Long non-coding RNAs (lncRNAs) have emerged as crucial regulators of cancer development and progression. Among them, Differentiation Antagonizing Non-Protein Coding RNA (DANCR) has been implicated in various malignancies, including esophageal squamous cell carcinoma (ESCC). This study explores the clinical characteristics, prognostic implications, functional roles, and molecular mechanisms of DANCR in ESCC.
View Article and Find Full Text PDFFront Oncol
February 2025
Department of Thoracic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Centromere protein H (CENP-H) is an important component of a functional centromere. Studies have demonstrated that CENP-H is overexpressed in renal cell, gastric, hypopharyngeal squamous cell, nasopharyngeal, endometrial, lung, cervical, esophageal, liver, colorectal, oral squamous cell, breast, and tongue carcinomas. CENP-H overexpression is positively correlated with a poor prognosis, pathological stage, T stage, and lymph node metastasis in patients with the above carcinomas.
View Article and Find Full Text PDFBMC Cancer
March 2025
Central Laboratory, School of Medicine, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, 361102, P.R. China.
Background: Esophageal squamous cell carcinoma (ESCC), the most common type of esophageal cancer, characterized by low five-year survival rate, and concurrent chemoradiotherapy (CCRT) has been proposed to treat ESCC, while potential biomarkers for prognostic monitoring after optimized CCRT remains unknown.
Methods: Serum samples from 45 patients with ESCC were collected and categorized into three groups: Control (pre-CCRT), CCRT (during CCRT), and CCRT-1 M (one-month post-CCRT). The therapeutic effect was evaluated using CT imaging and established evaluation criteria.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!